.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advancement in the management of wet AMD

Caroline R Baumal, MD, Thomas Albini, MD, Aleksandra Rachitskaya, MD, and Michael Singer, MD, discuss a number of topics pertaining to wet age-related macular degeneration (wet AMD) including the diagnosis and clinical manifestations, treatment options, and the impact of the COVID-19 pandemic on management of wet AMD.

Advancement in the management of wet AMD

EP. 1: Introduction and definition of macular degeneration

EP. 2: Identifying a typical patient with Wet AMD

EP. 3: Clinical trials vs real-world data on wet AMD

EP. 4: Anti-VEGF agents for treatment of wet AMD

EP. 5: Personal experience with anti-VEGF agents for wet AMD

EP. 6: Reasons for switching between agents for wet AMD

EP. 7: Safety concerns with anti-VEGF agents for wet AMD

EP. 8: Role of biosimilars in management of wet AMD

EP. 9: Compounds and home monitoring device in development for wet AMD

EP. 10: The impact of COVID-19 on the management of wet AMD